Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in late-stage clinical testing to prevent complications in patients with atrial ...

Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...

Thrombosis is a major unmet need. Globally more than one in four people die from thromboembolic events. Many more suffer morbidity due to complications. These events occur despite the availability ...

Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal ...

CAMBRIDGE, Mass., February 11, 2025--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc. ("Anthos" or the "company"), a transformative, clinical-stage biopharmaceutical company ...